288 related articles for article (PubMed ID: 27863566)
1. Molecular Imaging and Precision Medicine in Lung Cancer.
Zukotynski KA; Gerbaudo VH
PET Clin; 2017 Jan; 12(1):53-62. PubMed ID: 27863566
[TBL] [Abstract][Full Text] [Related]
2. Update on Molecular Imaging and Precision Medicine in Lung Cancer.
Zukotynski KA; Hasan OK; Lubanovic M; Gerbaudo VH
Radiol Clin North Am; 2021 Sep; 59(5):693-703. PubMed ID: 34392913
[TBL] [Abstract][Full Text] [Related]
3. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging and Precision Medicine in Breast Cancer.
Chudgar AV; Mankoff DA
PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
[TBL] [Abstract][Full Text] [Related]
5. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
Wright CL; Maly JJ; Zhang J; Knopp MV
PET Clin; 2017 Jan; 12(1):63-82. PubMed ID: 27863567
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM
PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging and Precision Medicine in Dementia and Movement Disorders.
Mallik AK; Drzezga A; Minoshima S
PET Clin; 2017 Jan; 12(1):119-136. PubMed ID: 27863563
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging and Precision Medicine in Head and Neck Cancer.
Mena E; Thippsandra S; Yanamadala A; Redy S; Pattanayak P; Subramaniam RM
PET Clin; 2017 Jan; 12(1):7-25. PubMed ID: 27863568
[TBL] [Abstract][Full Text] [Related]
9. Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer.
Detterbeck FC; Vansteenkiste JF; Morris DE; Dooms CA; Khandani AH; Socinski MA
Chest; 2004 Nov; 126(5):1656-66. PubMed ID: 15539740
[TBL] [Abstract][Full Text] [Related]
10. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
[TBL] [Abstract][Full Text] [Related]
11. [18Fluoro-deoxy-glucose positron emission tomography (18FGT-PET) and lung cancer].
Vaylet F; Foehrenbach H
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S16-21. PubMed ID: 15536347
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
13. Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer.
Zukotynski KA; Gaudet VC; Uribe CF; Chiam K; Bénard F; Gerbaudo VH
PET Clin; 2022 Jan; 17(1):77-84. PubMed ID: 34809872
[TBL] [Abstract][Full Text] [Related]
14. The Current and Evolving Role of PET in Personalized Management of Lung Cancer.
Mena E; Yanamadala A; Cheng G; Subramaniam RM
PET Clin; 2016 Jul; 11(3):243-59. PubMed ID: 27321029
[TBL] [Abstract][Full Text] [Related]
15. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence.
Novello S; Giaj Levra M; Vavalà T
Crit Rev Oncol Hematol; 2012 Aug; 83(2):208-15. PubMed ID: 22062925
[TBL] [Abstract][Full Text] [Related]
16. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
17. Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.
Basu S; Parghane RV
PET Clin; 2017 Jan; 12(1):27-37. PubMed ID: 27863564
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
19. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer.
Gregory DL; Brennan SM; Stillie A; Herschtal A; Hicks RJ; MacManus MP; Ball DL
J Med Imaging Radiat Oncol; 2010 Apr; 54(2):100-7. PubMed ID: 20518871
[TBL] [Abstract][Full Text] [Related]
20. Combined contrast-enhanced computed tomography and 18-fluoro-2-deoxy-D-glucose-positron emission tomography in the diagnosis and staging of non-small cell lung cancer.
Allen TL; Kendi AT; Mitiek MO; Maddaus MA
Semin Thorac Cardiovasc Surg; 2011; 23(1):43-50. PubMed ID: 21807298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
